Cardiovascular system state changes in non-Hodgkin’s lymphoma patients during chemotherapy
https://doi.org/10.15372/SSMJ20200210
Abstract
Chemotherapy is one of reliable and proven methods of malignant tumor and blood diseases treatment but however the drug side effects (particularly cardiotoxicity) occur. More often cardiovascular complications connect with anthracyclines and related drugs (doxorubicin, daunorubicyn, epirubicyn, idarubicyn, mitoxantron) which usually used at medical scheme because of wide spectrum of action and high effectiveness prescription. Risk of cardiotoxicity formation and existing diseases progression increases according to drug dose, patient’s age, cardiovascular risk factors presence and cardiovascular diseases history. Material and methods. 88 patients with established non-Hodgkin’s lymphoma diagnosis were examined in order to assess cardiovascular system state and pathology nature – 33 patients before chemotherapy and 55 patients in the long-term follow-up period (one year after the start of chemotherapy). Results. It was found that antitumor drugs induced cardiotoxicity may manifest at the beginning of chemotherapy as well as following up period. The cardiac cameras dilation associated with the increase of NTproBNP serum content (N-terminal fragment of natriuretic peptide type B precursor) – the main biomarker of myocardial dysfunction has been revealed by instrumental research.
About the Authors
A.-S. O. Bady
Novosibirsk State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Ay-Suu O-O. Bady
630091, Novosibirsk, Krasny av., 52
S. S. Fedorova
Novosibirsk State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Sof’ya S. Fedorova
630091, Novosibirsk, Krasny av., 52
D. A. Yakhontov
Novosibirsk State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Davyd A. Yakhontov, doctor of medical sciences
630091, Novosibirsk, Krasny av., 52
T. I. Pospelova
Novosibirsk State Medical University of Minzdrav of Russia
Russian Federation
Russian Federation
Tat’yana I. Pospelova, doctor of medical sciences, professor
630091, Novosibirsk, Krasny av., 52
References
1. Gadaev I.Yu., Ershov V.I., Bochkarnikova O.V., Sokolova I.Ya., Budanova D.A., Kotova V.S., Lishuta A.S. Cardiac involvement in lymphomas. Review of literature and case report of the clinical course of B-large-cell lymphoma. Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology, 2015; 11 (6): 610–617. [In Russian].
2. Gendlin G.E., Storozhakov G.I., Shuykova K.V., Emelina E.I., Klyushina G.M., Mironkov A.B., Ostroumova E.I., Lepkov S.V., Demina E.A. Acute cardiovascular events during antitumor drugs treatment: Clinical cases. Klinicheskaya onkogematologiya = Clinical Oncohematology. 2011; 4 (2): 155–165. [In Russian].
3. Dorokhina E.I., Magomedova F.U., Dvirnyk V.N., Galtseva I.V., Glinkina S.A., Kulikov S.M., Obukhova T.N., Kravchenko S.K. Late myelotoxicity of highdose chemotherapy according to the modified NHLBFM-90 program in adult patients with diffuse large B-cell lymphoma. Gematologiya i transfuziologiya = Hematology and Transfusiology. 2016; 61 (4): 177–183. [In Russian]. doi: 10.18821/0234-5730-2016-614-177-183
4. Emelina E.I., Gendlin G.E., Storozhakov G.I., Lepkov S.V., Demina E.A. Time course of echocardiographic changes in patients with lymphoproliferative diseases, receiving anthracyclines. Rossiyskiy meditsinskiy zhurnal = Russian Medical Journal. 2007; (1): 7–11 [In Russian].
5. Krikunova O.V., Vasyuk Yu.A., Viskov R.V., Krikunov P.V., Ivanova S.V., Konik V.A. Chemotherapy cardiotoxicity screening with cardiac troponins. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2015; (12): 119–125. [In Russian]. doi:
6. 15829/1560-4071-2015-12-119-125
7. Mareev V.Yu., Ageev F.T., Arutyunov G.P., Koroteyev A.V., Mareyev Yu.V., Ovchinnikov A.G., Belenkov Yu.N., Vasyuk Yu.A., Galyavich A.S., Garganeyeva A.A., Gilyarevskiy S.R., Glezer M.G., Koziolova N.A., Kots Ya.I., Lopatin Yu.M., Martynov A.I., Moiseyev V.S., Revishvili A.Sh., Sitnikova M.Yu., Skibitskiy V.V., Sokolov Ye.I., Storozhakov G.I., Fomin I.V., Chesnikova A.I., Shlyakhto Ye.V. SEHF, RSC and RSMSIM national guidelines on CHF diagnostics and treatment (fourth revision). Zhurnal serdechnaya тedostatochnost’ = Heart Failure Journal. 2013; 14 (7): 379–472. [In Russian].
8. Poddubnaya I.V. Non-Hodgkin’s lymphomas. In: Clinical hematology: A guide for physicians. Ed. V.A. Volkova. Chapter 23. Moscow: Meditsina, 2001. Р. 336–375 [In Russian].
9. Shuykova K.V., Emelina E.I., Gendlin G.I., Storozhakov G.I. Change of the left ventricle n lymphoma treated with anthracycline antibiotics. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2016; 1 (129): 41–46. [In Russian]. doi: 10.15829/1560-4071-2016-1-41-46
10. Hennessy B.T., Hanrahan E.O., Daly P.A. Non Hodgkin’s lymphoma: an update. Lancet Oncol. 2004; 5: 341–353. doi: 10.1016/S1470-2045(04)01490-1
11. Raj S., Franco V.I., Lipshultz S.E. Anthracycline-incluced cardiotoxity; a review of pathophysiology, diagnosis, and treatment. Curr. Treat. Options Cardiovasc. Med. 2014; 16 (6): 315. doi: 10.1007/s11936-014-0315-4
12. Vergely C., Delemasure S., Cottin Y., R te L. Preventing the cardiotoxic effects of anthracyclins: from basic concepts to clinical data. Heart Metab. 2007; 35: 1–7.
Review
Views:
356
Email this article 